CDK4 and breast cancer: Given that the retinoblastoma protein (RB) is the main phosphorylation target of CDK4/6 to stimulate cell cycle progression, inactivating mutations or the loss of the RB1 gene was found in different BC patients with reduced sensitivity to CDK4/6 inhibitors [46,47].